Geographic atrophy (GA) is a condition that typically progresses slowly, with lesions expanding by about 1 square millimeter per year, leading to blind spots due to retinal deterioration. Treatment ...

—Certain imaging biomarkers and demographic factors are associated with geographic atrophy growth rate and may guide the selection of patients for the use of newer therapeutics. As the population ...

While there is currently no cure for geographic atrophy, certain treatments, such as complement inhibitors, can help slow its progression by targeting immune system activity that damages the macula.

Geographic atrophy (GA), the late stage of age-related macular degeneration (AMD), may lead to vision loss. Here’s what to expect as the condition progresses. About 1 million people in the United ...

Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that results in progressive and irreversible vision loss, particularly in older adults. It occurs due to the ...

A novel outcome measure for geographic atrophy, the Geographic Atrophy Weighted-by-Acuity Index, aligned with best-corrected visual acuity, showing better correlation and predictive accuracy than the ...

Please provide your email address to receive an email when new articles are posted on . The first disease-modifying therapies have transformed the management of geographic atrophy. Patient selection ...

The following slide deck was published by Annexon, Inc. in conjunction with this event.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In 2024, Healio covered several stories about trials ...

Age is a major risk factor for geographic atrophy (GA). As the eyes age, natural defenses weaken, blood flow may decline, and waste removal may slow, allowing deposits called drusen to build up.

The earlier patients with potentially blinding geographic atrophy start treatment with the complement inhibitor pegcetacoplan, the more retinal tissue they retain 4 years later compared with patients ...